This page separates registered trial information from statistical interpretation. The ClinicalTrials.gov record identifies the trial as randomized and phase 3, but it does not list registered primary endpoints or posted statistical analyses.
1. Trial at a Glance
AFFIRM was a phase 3, randomized treatment trial concerning atrial fibrillation and related cardiovascular conditions. The registry identifies the study as the Atrial Fibrillation Follow-up Investigation of Rhythm Management and lists a broad set of pharmacologic, procedural, and device interventions.
| Feature | AFFIRM |
|---|---|
| Official title | Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) |
| NCT identifier | NCT00000556 |
| Phase | Phase 3 |
| Status | Completed |
| Start date | 1995-03 |
| Allocation | Randomized |
| Primary purpose | Treatment |
| Conditions | Arrhythmia; Atrial Fibrillation; Cardiovascular Diseases; Heart Diseases |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Sponsor type | NIH |
2. Clinical Question
The registry identifies AFFIRM as a randomized phase 3 treatment study in the setting of atrial fibrillation. The study title specifically identifies the investigation as one of rhythm management.
Population
The registry lists arrhythmia, atrial fibrillation, cardiovascular diseases, and heart diseases as the study conditions. The ClinicalTrials.gov record does not provide an enrollment count or a detailed baseline population description.
Intervention strategy
The intervention list includes antiarrhythmic drugs, rate-control medications, catheter ablation, and an artificial pacemaker.
Comparator
The ClinicalTrials.gov record identifies the allocation as randomized but does not provide a separate comparator description in the registered intervention information.
Primary question
The study title frames the investigation around rhythm management in atrial fibrillation. The ClinicalTrials.gov record does not list a registered primary endpoint that defines the formal statistical comparison.
3. Trial Design
Intervention framework
Antiarrhythmic and cardiovascular drugs
- Amiodarone
- Sotalol
- Propafenone
- Flecainide
- Quinidine
- Moricizine
- Disopyramide
- Procainamide
- Adrenergic beta antagonists
- Verapamil
- Diltiazem
- Digoxin
Nonpharmacologic management
- Catheter ablation
- Pacemaker, artificial
The breadth of the intervention list is statistically important. It indicates that the study concerns management strategies rather than a simple single-drug-versus-placebo experiment. However, the ClinicalTrials.gov record does not specify how these individual interventions were distributed among randomized groups.
4. Endpoints
| Endpoint information | Registry record |
|---|---|
| Registered primary endpoints | None listed |
| Primary endpoint definitions | Not reported |
| Primary endpoint time frames | Not reported |
| Posted statistical analyses | None listed |
This distinction matters because the statistical method cannot be selected independently of the endpoint. A continuous endpoint, binary endpoint, count endpoint, time-to-event endpoint, and repeated-measures endpoint each requires a different analysis framework. Without a registered endpoint definition, assigning a particular primary analysis to AFFIRM would go beyond the registry record.
5. Statistical Methodology
The most important statistical feature explicitly identified by the registry is randomized allocation. Randomization is the central design mechanism for creating comparable treatment groups in expectation and for supporting a causal comparison of assigned treatment strategies.
Randomization
In a randomized trial, treatment assignment is determined by the study's allocation mechanism rather than by the investigator's or patient's prognostic characteristics. This allows the treatment comparison to be interpreted using the randomization distribution as the foundation for statistical inference.
The statistical analysis should preserve the distinction between the treatment assigned by randomization and the treatment actually received. The ClinicalTrials.gov record does not identify the specific analysis populations used by AFFIRM.
Endpoint-dependent analysis
Because no registered primary endpoints are listed, the registry record does not establish whether the primary analysis was based on survival time, a binary outcome, a continuous measurement, a count, or another endpoint type.
| Endpoint type | Typical statistical framework | What would determine the choice |
|---|---|---|
| Time-to-event | Kaplan-Meier estimation, event-time comparison, and possibly a proportional-hazards model | Whether the endpoint is defined as time until an event and how censoring is handled |
| Binary | Risk difference, risk ratio, odds ratio, or regression-based comparison | The prespecified event definition and analysis population |
| Continuous | Difference in means or model-based comparison | The measurement scale and prespecified adjustment variables |
| Repeated measures | Longitudinal or mixed-effects modeling | Repeated observations and their correlation structure |
These are statistical frameworks rather than identified AFFIRM results. The appropriate method would depend on the endpoint definition, follow-up structure, censoring, missingness, and prespecified analysis plan.
Randomized comparison versus observed treatment
A randomized analysis generally asks whether outcomes differ according to the treatment strategy assigned at randomization. An analysis based only on treatment actually received answers a different question because treatment received can be affected by clinical events occurring after randomization.
This distinction becomes particularly important in a trial with a broad intervention list. If participants can receive different pharmacologic or procedural treatments over time, the analysis must distinguish the original randomized strategy from subsequent treatment exposure.
6. Planned Analysis
The registry identifies AFFIRM as a randomized phase 3 treatment study, but no registered primary endpoints or posted statistical analyses are listed in the record.
For a randomized trial of this type, the statistical analysis would ordinarily begin by specifying:
- the exact primary endpoint and its operational definition;
- the analysis population, including how randomized participants are handled;
- the treatment contrast corresponding to the randomization;
- the estimand or effect measure used to quantify the treatment difference;
- the hypothesis-testing framework and confidence-interval procedure;
- the handling of missing observations, withdrawals, and treatment changes; and
- any prespecified adjustment for stratification, covariates, repeated measurements, or multiple endpoints.
For a time-to-event endpoint, a typical analysis would describe the event definition, censoring rules, Kaplan-Meier estimates, an appropriate between-group comparison, and a model-based effect measure when justified. For a binary endpoint, the analysis would instead focus on event probabilities and a prespecified comparative effect measure. For a continuous endpoint, the analysis would focus on between-group differences in the measured outcome.
7. Statistical Methods Explained
Why does randomization matter statistically?
Randomization creates the reference distribution for the treatment comparison. If treatment assignment is genuinely randomized, differences in outcomes can be evaluated against what would be expected from random assignment rather than relying on adjustment for every potentially relevant prognostic factor.
Why can't the primary statistical test be identified from the study phase alone?
Phase 3 describes the stage of clinical development, not the mathematical form of the endpoint. A phase 3 trial can use survival, binary, continuous, count, or repeated-measures endpoints. The endpoint definition determines the appropriate statistical analysis.
Why is the intervention list statistically important?
A single-drug trial can often be represented by a straightforward treatment-versus-control contrast. AFFIRM's registry intervention list includes numerous antiarrhythmic drugs, cardiovascular drugs, catheter ablation, and an artificial pacemaker. That makes the exact treatment-strategy definition essential to interpreting any eventual treatment effect.
What does “primary purpose: treatment” tell us?
It identifies the main purpose of the study as evaluating treatment rather than prevention, diagnosis, basic science, or another study purpose. It does not specify the primary endpoint or the statistical test.
Why is an enrollment count important?
Sample size determines the amount of information available for estimating treatment effects and affects the precision of confidence intervals and the ability to detect differences. The ClinicalTrials.gov record does not report an enrollment number, so the statistical information content of the study cannot be characterized from that field.
Why should missing endpoint definitions not be replaced by assumptions?
A statistical result has meaning only in relation to a precisely defined estimand and endpoint. For example, “survival” can refer to different event definitions and analysis conventions. Replacing an absent registry endpoint with a presumed one could change the question being answered.
8. Statistical Interpretation of the Trial Design
The designation randomized describes how treatment allocation was performed. It does not imply that one treatment strategy produced a statistically significant benefit. That conclusion requires a prespecified endpoint, an appropriate analysis, an effect estimate, and corresponding uncertainty or hypothesis-testing information.
A phase 3 designation identifies the development phase of the study. It does not establish the magnitude, direction, or precision of a treatment effect. Those properties come from the endpoint-specific statistical analysis.
The presence of amiodarone, sotalol, propafenone, flecainide, and the other listed interventions describes what the registry records as interventions. It does not by itself establish which intervention was superior, whether any difference was statistically significant, or how treatments were compared.
The ClinicalTrials.gov record represented here contains no posted statistical analyses. Therefore, the registry establishes the study design and intervention framework but does not provide a registry-based numerical estimate of treatment effect to interpret.
9. Design Features and What They Imply for Analysis
| Design feature | Statistical implication |
|---|---|
| Randomized allocation | Supports comparison according to assigned treatment strategy. |
| Phase 3 | Indicates a late clinical-development phase but does not specify the endpoint analysis. |
| Primary purpose: treatment | Frames the study around evaluation of treatment strategies. |
| Multiple listed interventions | Requires clear definition of the treatment strategy and comparison being analyzed. |
| Completed status | Indicates that the registry records the study as completed; it does not supply an endpoint result. |
| No registered primary endpoints listed | Prevents identification of a registry-defined primary estimand or confirmatory statistical test. |
| No posted statistical analyses | No registry-based effect estimate, confidence interval, or p-value is available in the ClinicalTrials.gov record. |
10. Interpreting Pharmacologic and Procedural Strategies
The intervention list is unusually broad from a statistical-analysis perspective. It includes both medications and procedures/devices. A statistical comparison involving such a strategy must distinguish the assigned management strategy from individual therapies that may be used within or after that strategy.
For example, amiodarone and catheter ablation are fundamentally different intervention modalities. Treating every item in the registry intervention list as if it were an independent randomized treatment arm would be inappropriate unless the trial's allocation scheme explicitly established those arms.
Strategy-level question
Does assignment to a specified management strategy change the prespecified clinical endpoint compared with the randomized comparator strategy?
Component-level question
Does a particular drug or procedure independently affect the endpoint? This requires a design and analysis capable of isolating that component.
Post-randomization exposure
Therapies received after randomization can be affected by events occurring during follow-up, complicating simple comparisons based on treatment actually received.
Device and procedure effects
Catheter ablation and artificial pacemaker use introduce procedural and device exposure considerations that differ from conventional drug comparisons.
11. Missingness, Follow-up, and Censoring
Any longitudinal clinical-trial analysis must define how incomplete follow-up is handled. The relevant issues depend on the endpoint. For a time-to-event endpoint, a participant who has not experienced the event by the end of available observation may be censored. For a binary endpoint, an incomplete observation may instead require an explicit missing-data rule.
The registry information posted on ClinicalTrials.gov for AFFIRM does not specify its primary endpoint, missing-data rules, censoring rules, or imputation method. These details are therefore essential components of any full statistical analysis but cannot be identified from the registry fields represented here.
A censored participant is not automatically equivalent to a participant who experienced the event. The validity of the analysis depends on prespecified censoring rules and assumptions about the relationship between censoring and the event process.
12. Multiplicity and Multiple Comparisons
Multiplicity becomes important whenever a trial makes several formal statistical claims. Multiple primary endpoints, multiple treatment comparisons, repeated interim looks, or numerous confirmatory subgroup tests can increase the probability of at least one false-positive finding if they are treated as independent tests without appropriate error control.
The registry-reported AFFIRM registry information does not identify a primary endpoint hierarchy, multiplicity strategy, alpha-spending procedure, or formal adjustment for multiple comparisons.
13. Interim Analysis
An interim analysis is a statistical evaluation conducted before the planned end of follow-up or information accumulation. Interim monitoring can be useful for ethical and operational reasons, but repeated unadjusted testing of accumulating data can alter the probability of a false-positive result.
The ClinicalTrials.gov record represented here does not list an interim-analysis plan, stopping boundary, alpha-spending method, or information fraction. Those design elements therefore cannot be attributed to AFFIRM from this registry record.
14. Stratification and Covariate Adjustment
Stratification can be incorporated into randomization and/or analysis to account for prespecified prognostic factors. Covariate adjustment can also improve precision when appropriate variables are specified in advance and modeled correctly.
No stratification factors or prespecified covariates are identified in the ClinicalTrials.gov record. Consequently, a stratified statistical model or adjusted regression analysis cannot be assigned to AFFIRM without additional documentation.
15. Non-Inferiority, Equivalence, and Superiority Logic
The registry information does not identify AFFIRM as a non-inferiority or equivalence trial, and it does not provide a non-inferiority margin.
That distinction is important because non-inferiority trials require a prespecified margin defining how much loss of efficacy would still be considered compatible with the trial's objective. A superiority analysis asks a different question and uses a different inferential framework.
| Framework | Core question | Required design element |
|---|---|---|
| Superiority | Is one strategy associated with a greater favorable effect than another? | Prespecified superiority hypothesis and endpoint |
| Non-inferiority | Is the new strategy sufficiently close to the comparator within a prespecified acceptable margin? | Non-inferiority margin and appropriate confidence-interval interpretation |
| Equivalence | Are the strategies sufficiently close in both directions within predefined bounds? | Two-sided equivalence margins and appropriate confidence-interval assessment |
16. Bayesian Methods
The ClinicalTrials.gov record does not identify a Bayesian statistical framework for AFFIRM. Bayesian analysis would require explicit specification of prior distributions, a likelihood or probability model, and an inferential quantity such as a posterior probability or credible interval.
Without such information, the presence of a randomized design should not be interpreted as evidence for either a frequentist or Bayesian analysis. Randomization and inferential framework are separate aspects of trial methodology.
17. Analysis Population
The registry record identifies the allocation as randomized but does not specify an intention-to-treat population, per-protocol population, as-treated population, or other formal analysis set.
For randomized trials, the analysis population is a substantive statistical decision. An intention-to-treat analysis preserves the original treatment assignment and therefore maintains the primary advantage created by randomization. An as-treated analysis instead groups participants according to treatment received and may introduce post-randomization differences between groups.
Intention-to-treat
Participants remain associated with their randomized assignment for the primary comparison.
As-treated
Participants are analyzed according to treatment received, which can be affected by events after randomization.
Neither approach should be attributed to AFFIRM without documentation identifying the analysis population.
18. Statistical Questions a Full AFFIRM Analysis Would Need to Answer
A complete statistical evaluation of the randomized treatment comparison would need to establish several linked quantities before an effect could be interpreted.
| Question | Why it matters |
|---|---|
| What is the primary endpoint? | Defines exactly what outcome the trial was designed to compare. |
| What is the estimand? | Defines the treatment effect being estimated and the population, outcome, and intercurrent-event strategy relevant to that effect. |
| What is the randomized contrast? | Defines which treatment strategies are being compared. |
| What is the analysis population? | Determines which participants contribute to the formal inference. |
| How are missing observations handled? | Determines how incomplete information enters the analysis. |
| What is the effect measure? | Determines whether the result is expressed as a difference, ratio, hazard ratio, odds ratio, or another quantity. |
| How is uncertainty quantified? | Confidence or credible intervals show the precision associated with the estimated effect. |
| How is multiplicity controlled? | Determines how multiple formal claims affect type I error. |
19. Limitations
- Primary endpoint information: the ClinicalTrials.gov record does not list registered primary endpoints for this study.
- Enrollment: an enrollment number is not reported in the ClinicalTrials.gov record.
- Effect estimates: no posted statistical analyses are listed, so the registry record does not provide an effect estimate, confidence interval, or p-value for a primary endpoint.
- Analysis population: the record does not identify whether efficacy analyses used an intention-to-treat, per-protocol, or other analysis set.
- Endpoint-specific methodology: without a registered primary endpoint, a specific primary statistical model cannot be identified from the registry.
- Intervention structure: the registry lists numerous pharmacologic, procedural, and device interventions without specifying their randomized allocation structure in the ClinicalTrials.gov record.
- Missing-data methods: censoring, imputation, and missing-data rules are not identified in the ClinicalTrials.gov record.
- Multiplicity: the ClinicalTrials.gov record does not identify an endpoint hierarchy or multiplicity-adjustment strategy.
- Interim monitoring: no interim-analysis or stopping-boundary framework is identified in the ClinicalTrials.gov record.
- Generalizability: the limited registry information represented here does not provide the detailed eligibility, demographic, clinical, or site-level characteristics needed to assess the representativeness of the enrolled population.
20. Why This Trial Matters Statistically
AFFIRM is a useful statistical case study because its title and registry structure place the central question in the domain of treatment strategy rather than a narrowly defined single-drug experiment. The registry identifies randomization, a phase 3 treatment purpose, and a broad set of interventions that span pharmacologic, procedural, and device-based management.
That structure illustrates an important principle in clinical-trial statistics: the treatment question must be defined before the statistical model is chosen. A statistical model cannot compensate for an ambiguous treatment contrast or an incompletely defined endpoint.
| Concept | How it appears in AFFIRM |
|---|---|
| Randomization | The registry explicitly identifies allocation as randomized. |
| Phase 3 design | The study is identified as phase 3. |
| Treatment evaluation | Primary purpose is listed as treatment. |
| Strategy-level analysis | The title identifies an investigation of rhythm management. |
| Multiple intervention modalities | The intervention list includes drugs, catheter ablation, and an artificial pacemaker. |
| Endpoint specification | No registered primary endpoints are listed in the ClinicalTrials.gov record. |
| Statistical inference | No posted statistical analyses are listed in the ClinicalTrials.gov record. |
21. The Difference Between a Trial Design and a Trial Result
The registry establishes that AFFIRM is a randomized phase 3 treatment study. This tells the reader how the study is structured and what broad clinical purpose it serves.
A result would require an observed endpoint, a treatment contrast, an effect estimate, and an appropriate measure of uncertainty. None of those primary statistical results are posted in the ClinicalTrials.gov record represented here.
Statistical inference connects the observed data to a prespecified hypothesis or estimand. Without the endpoint definition and analysis framework, a numerical inference cannot be reconstructed from the registry design fields alone.
This distinction is especially important for educational interpretation. Knowing that a study is randomized does not identify its treatment effect, and knowing that it is phase 3 does not establish statistical significance. Those conclusions come from the endpoint-specific analysis.
22. What the Registry Does and Does Not Establish
| Established by the record | Not reported in the ClinicalTrials.gov record |
|---|---|
| AFFIRM is a phase 3 study. | Enrollment number. |
| The study is completed. | Registered primary endpoints. |
| Allocation is randomized. | Primary endpoint definitions and time frames. |
| The primary purpose is treatment. | Primary effect estimates. |
| The study concerns atrial fibrillation and related cardiovascular conditions. | Confidence intervals and p-values. |
| The intervention list includes the specified drugs, catheter ablation, and artificial pacemaker. | Posted statistical analyses. |
| The lead sponsor is NHLBI. | Analysis populations, missing-data methods, and multiplicity procedures. |
| The study began in 1995-03. | Specific statistical model used for a primary endpoint. |
23. Sources
- ClinicalTrials.gov: NCT00000556 — Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM).
Continue through the Clinical Biostats clinical-trial library
Clinical trial analysis is most useful when study design, endpoint definition, treatment contrast, statistical model, and uncertainty are interpreted together.
24. Record Summary
AFFIRM is recorded by ClinicalTrials.gov as a completed, randomized phase 3 treatment study that began in 1995-03 and investigated rhythm management in the setting of atrial fibrillation and related cardiovascular conditions. The intervention list spans multiple antiarrhythmic and cardiovascular drugs as well as catheter ablation and an artificial pacemaker. From a statistical perspective, the most important documented design feature is randomized allocation. At the same time, the registry record represented here does not list registered primary endpoints, enrollment, or posted statistical analyses. The appropriate interpretation is therefore centered on the structure of randomized clinical-trial inference: the endpoint defines the estimand, the treatment contrast defines the comparison, and the prespecified analysis determines how the observed data are translated into an effect estimate and its uncertainty.